@sejalsriv.bsky.social
Reposted
Super exciting application of new outcomes-based pricing models for ultra-expensive cell & gene therapies!
Under this model, manufacturers of Casgevy ($2.2M) and Lyfgenia ($3.1M) have agreed that cost to Medicaid will be a function of drug efficacy in patients.
Under this model, manufacturers of Casgevy ($2.2M) and Lyfgenia ($3.1M) have agreed that cost to Medicaid will be a function of drug efficacy in patients.
In Brief: bluebird bio and @vertexpharma.bsky.social are the first to participate in a scheme to enable people with sickle cell disease to access treatments they would otherwise not be able to afford nature.com/articles/s41...
rdcu.be/d7Hss
rdcu.be/d7Hss
Pricey sickle cell gene therapies primed for change - Nature Biotechnology
Nature Biotechnology - Pricey sickle cell gene therapies primed for change
nature.com
January 28, 2025 at 10:40 PM
Super exciting application of new outcomes-based pricing models for ultra-expensive cell & gene therapies!
Under this model, manufacturers of Casgevy ($2.2M) and Lyfgenia ($3.1M) have agreed that cost to Medicaid will be a function of drug efficacy in patients.
Under this model, manufacturers of Casgevy ($2.2M) and Lyfgenia ($3.1M) have agreed that cost to Medicaid will be a function of drug efficacy in patients.